A single centre, randomised, double-blind, double-dummy, placebo-and active-controlled, 3-way cross-over study to evaluate the 24 hour FEV1 profile of a single dose of CHF 5188 pMDI (400/4 mcg QD) (fixed combination budesonide/carmoterol 200/2 mcg) in adults patients with moderate or severe persistent asthma.
Latest Information Update: 31 Oct 2011
At a glance
- Drugs Budesonide/carmoterol (Primary) ; Budesonide/formoterol
- Indications Asthma
- Focus Therapeutic Use
- 29 Jul 2011 New trial record